Candidate genes for Parkinson disease: Lessons from pathogenesis

Clinica Chimica Acta

Volumn 449, Issue , 2015, Pages 68-76

  De Rosa, Priscilla ^a   Marini, Elettra Sara ^a,b   Gelmetti, Vania ^a   Valente, Enza Maria ^a,c  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

Author keywords

Autophagy; Genetics; Inflammation; Misfolded protein damage; Mitochondria; Parkinson disease

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BETA GLUCOCEREBROSIDASE; CALCIUM; GLUCOSYLCERAMIDASE; LEUCINE RICH REPEAT KINASE 2; PARKIN; PROTEASOME; UBIQUITIN; UNCLASSIFIED DRUG;

ATP13A2 GENE; AUTOPHAGY; CALCIUM HOMEOSTASIS; CALCIUM METABOLISM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOPLASMIC RETICULUM STRESS; FAMILY HISTORY; FBXO7 GENE; GBA GENE; GENE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HIGH THROUGHPUT SEQUENCING; HUMAN; INFLAMMATION; METABOLIC CLEARANCE; MITOCHONDRIAL RESPIRATION; MITOPHAGY; MOLECULAR GENETICS; MULTIFACTORIAL INHERITANCE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKIN GENE; PARKINSON DISEASE; PINK1 GENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFECT; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; PROCEDURES;

AUTOPHAGY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PARKINSON DISEASE;

EID: 84940437391     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.04.042     Document Type: Review

References (129)

1. Wirdefeldt K., Adami H.O., Cole P., Trichopoulos D., Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 2011, 26(Suppl. 1):S1-S58.
2. Elbaz A., Moisan F. Update in the epidemiology of Parkinson's disease. Curr Opin Neurol 2008, 21:454-460.
3. Petrucci S., Consoli F., Valente E.M. Parkinson disease genetics: a "continuum" from Mendelian to multifactorial inheritance. Curr Mol Med 2014, 14:1079-1088.
4. Verstraeten A., Theuns J., Van Broeckhoven C. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet 2015, 31:140-149.
5. Quadri M., Yang X., Cossu G., Olgiati S., Saddi V.M., Breedveld G.J., et al. An exome study of Parkinson's disease in Sardinia, a Mediterranean genetic isolate. Neurogenetics 2015, 16:55-64.
6. Dexter D.T., Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 2013, 62:132-144.
7. Valente E.M., Arena G., Torosantucci L., Gelmetti V. Molecular pathways in sporadic PD. Parkinsonism Relat Disord 2012, 18(Suppl. 1):S71-S73.
8. Atkin G., Paulson H. Ubiquitin pathways in neurodegenerative disease. Front Mol Neurosci 2014, 7:63.
9. McNaught K.S., Mytilineou C., Jnobaptiste R., Yabut J., Shashidharan P., Jennert P., et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem 2002, 81:301-306.
10. Rideout H.J., Larsen K.E., Sulzer D., Stefanis L. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J Neurochem 2001, 78:899-908.
11. McNaught K.S., Belizaire R., Isacson O., Jenner P., Olanow C.W. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 2003, 179:38-46.
12. Kim W.S., Kagedal K., Halliday G.M. Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther 2014, 6:73.
13. Wales P., Pinho R., Lazaro D.F., Outeiro T.F. Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration. J Park Dis 2013, 3:415-459.
14. Ciechanover A., Kwon Y.T. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. Exp Mol Med 2015, 47:e147.
15. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., et al. Mutations in the Parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392:605-608.
16. Imai Y., Soda M., Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem 2000, 275:35661-35664.
17. Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y., Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 2001, 105:891-902.
18. Shin J.H., Ko H.S., Kang H., Lee Y., Lee Y.I., Pletinkova O., et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 2011, 144:689-702.
19. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., et al. Ubiquitination of a new form of alpha-synuclein by Parkin from human brain: implications for Parkinson's disease. Science 2001, 293:263-269.
20. Di Fonzo A., Dekker M.C., Montagna P., Baruzzi A., Yonova E.H., Correia Guedes L., et al. FBXO7 mutations cause autosomal recessive, early-onset Parkinsonian-pyramidal syndrome. Neurology 2009, 72:240-245.
21. Nelson D.E., Randle S.J., Laman H. Beyond ubiquitination: the atypical functions of Fbxo7 and other F-box proteins. Open Biol 2013, 3:130131.
22. Zhao T., Severijnen L.A., van der Weiden M., Zheng P.P., Oostra B.A., Hukema R.K., et al. FBXO7 immunoreactivity in alpha-synuclein-containing inclusions in Parkinson disease and multiple system atrophy. J Neuropathol Exp Neurol 2013, 72:482-488.
23. Liu Y., Chen Y.Y., Liu H., Yao C.J., Zhu X.X., Chen D.J., et al. Association between ubiquitin carboxy-terminal hydrolase-L1 S18Y variant and risk of Parkinson's disease: the impact of ethnicity and onset age. Neurol Sci 2015, 36:179-188.
24. Lincoln S., Vaughan J., Wood N., Baker M., Adamson J., Gwinn-Hardy K., et al. Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease. Neuroreport 1999, 10:427-429.
25. Cartier A.E., Ubhi K., Spencer B., Vazquez-Roque R.A., Kosberg K.A., Fourgeaud L., et al. Differential effects of UCHL1 modulation on alpha-synuclein in PD-like models of alpha-synucleinopathy. PLoS One 2012, 7:e34713.
26. Liu Y., Fallon L., Lashuel H.A., Liu Z., Lansbury P.T. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 2002, 111:209-218.
27. Nikoletopoulou V., Papandreou M.E., Tavernarakis N. Autophagy in the physiology and pathology of the central nervous system. Cell Death Differ 2015, 22:398-407.
28. Hara T., Nakamura K., Matsui M., Yamamoto A., Nakahara Y., Suzuki-Migishima R., et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441:885-889.
29. Komatsu M., Waguri S., Chiba T., Murata S., Iwata J., Tanida I., et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441:880-884.
30. Nixon R.A., Yang D.S., Lee J.H. Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy 2008, 4:590-599.
31. Sarkar S. Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers. Biochem Soc Trans 2013, 41:1103-1130.
32. Sidransky E., Nalls M.A., Aasly J.O., Aharon-Peretz J., Annesi G., Barbosa E.R., et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009, 361:1651-1661.
33. Mazzulli J.R., Xu Y.H., Sun Y., Knight A.L., McLean P.J., Caldwell G.A., et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011, 146:37-52.
34. Schondorf D.C., Aureli M., McAllister F.E., Hindley C.J., Mayer F., Schmid B., et al. iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. Nat Commun 2014, 5:4028.
35. Schultheis P.J., Hagen T.T., O'Toole K.K., Tachibana A., Burke C.R., McGill D.L., et al. Characterization of the P5 subfamily of P-type transport ATPases in mice. Biochem Biophys Res Commun 2004, 323:731-738.
36. Ramirez A., Heimbach A., Grundemann J., Stiller B., Hampshire D., Cid L.P., et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006, 38:1184-1191.
37. Park J.S., Mehta P., Cooper A.A., Veivers D., Heimbach A., Stiller B., et al. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism. Hum Mutat 2011, 32:956-964.
38. Matsui H., Sato F., Sato S., Koike M., Taruno Y., Saiki S., et al. ATP13A2 deficiency induces a decrease in cathepsin D activity, fingerprint-like inclusion body formation, and selective degeneration of dopaminergic neurons. FEBS Lett 2013, 587:1316-1325.
39. Dehay B., Ramirez A., Martinez-Vicente M., Perier C., Canron M.H., Doudnikoff E., et al. Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci U S A 2012, 109:9611-9616.
40. Usenovic M., Tresse E., Mazzulli J.R., Taylor J.P., Krainc D. Deficiency of ATP13A2 leads to lysosomal dysfunction, alpha-synuclein accumulation, and neurotoxicity. J Neurosci 2012, 32:4240-4246.
41. Winslow A.R., Chen C.W., Corrochano S., Acevedo-Arozena A., Gordon D.E., Peden A.A., et al. Alpha-synuclein impairs macroautophagy: implications for Parkinson's disease. J Cell Biol 2010, 190:1023-1037.
42. Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292-1295.
43. Higashi S., Moore D.J., Yamamoto R., Minegishi M., Sato K., Togo T., et al. Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in Lewy body disease. J Neuropathol Exp Neurol 2009, 68:994-1005.
44. Dodson M.W., Zhang T., Jiang C., Chen S., Guo M. Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum Mol Genet 2012, 21:1350-1363.
45. Gomez-Suaga P., Rivero-Rios P., Fdez E., Blanca Ramirez M., Ferrer I., Aiastui A., et al. LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity. Hum Mol Genet 2014, 23:6779-6796.
46. MacLeod D.A., Rhinn H., Kuwahara T., Zolin A., Di Paolo G., McCabe B.D., et al. RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron 2013, 77:425-439.
47. Zimprich A., Benet-Pages A., Struhal W., Graf E., Eck S.H., Offman M.N., et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 2011, 89:168-175.
48. Tong Y., Giaime E., Yamaguchi H., Ichimura T., Liu Y., Si H., et al. Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegener 2012, 7:2.
49. Alegre-Abarrategui J., Christian H., Lufino M.M., Mutihac R., Venda L.L., Ansorge O., et al. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet 2009, 18:4022-4034.
50. Manzoni C., Mamais A., Dihanich S., Abeti R., Soutar M.P., Plun-Favreau H., et al. Inhibition of LRRK2 kinase activity stimulates macroautophagy. Biochim Biophys Acta 1833, 2013:2900-2910.
51. Miura E., Hasegawa T., Konno M., Suzuki M., Sugeno N., Fujikake N., et al. VPS35 dysfunction impairs lysosomal degradation of alpha-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease. Neurobiol Dis 2014, 71:1-13.
52. Grenier K., McLelland G.L., Fon E.A. Parkin- and PINK1-dependent mitophagy in neurons: will the real pathway please stand up?. Front Neurol 2013, 4:100.
53. Exner N., Lutz A.K., Haass C., Winklhofer K.F. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J 2012, 31:3038-3062.
54. Jin S.M., Youle R.J. PINK1- and Parkin-mediated mitophagy at a glance. J Cell Sci 2012, 125:795-799.
55. Burchell V.S., Nelson D.E., Sanchez-Martinez A., Delgado-Camprubi M., Ivatt R.M., Pogson J.H., et al. The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy. Nat Neurosci 2013, 16:1257-1265.
56. McCoy M.K., Cookson M.R. DJ-1 regulation of mitochondrial function and autophagy through oxidative stress. Autophagy 2011, 7:531-532.
57. Thomas K.J., McCoy M.K., Blackinton J., Beilina A., van der Brug M., Sandebring A., et al. DJ-1 acts in parallel to the PINK1/Parkin pathway to control mitochondrial function and autophagy. Hum Mol Genet 2011, 20:40-50.
58. Irrcher I., Aleyasin H., Seifert E.L., Hewitt S.J., Chhabra S., Phillips M., et al. Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics. Hum Mol Genet 2010, 19:3734-3746.
59. Gonzalez-Polo R., Niso-Santano M., Moran J.M., Ortiz-Ortiz M.A., Bravo-San Pedro J.M., Soler G., et al. Silencing DJ-1 reveals its contribution in paraquat-induced autophagy. J Neurochem 2009, 109:889-898.
60. Gao H., Yang W., Qi Z., Lu L., Duan C., Zhao C., et al. DJ-1 protects dopaminergic neurons against rotenone-induced apoptosis by enhancing ERK-dependent mitophagy. J Mol Biol 2012, 423:232-248.
61. Zhu Y., Wang C., Yu M., Cui J., Liu L., Xu Z. ULK1 and JNK are involved in mitophagy incurred by LRRK2 G2019S expression. Protein Cell 2013, 4:711-721.
62. Cherra S.J., Steer E., Gusdon A.M., Kiselyov K., Chu C.T. Mutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neurons. Am J Pathol 2013, 182:474-484.
63. Grunewald A., Arns B., Seibler P., Rakovic A., Munchau A., Ramirez A., et al. ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome. Neurobiol Aging 1843, 2012(33):e1-e7.
64. Su B., Wang X., Zheng L., Perry G., Smith M.A., Zhu X. Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochim Biophys Acta 1802, 2010:135-142.
65. Lackner L.L. Shaping the dynamic mitochondrial network. BMC Biol 2014, 12:35.
66. Chen H., Chomyn A., Chan D.C. Disruption of fusion results in mitochondrial heterogeneity and dysfunction. J Biol Chem 2005, 280:26185-26192.
67. Delettre C., Lenaers G., Griffoin J.M., Gigarel N., Lorenzo C., Belenguer P., et al. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet 2000, 26:207-210.
68. Zuchner S., Mersiyanova I.V., Muglia M., Bissar-Tadmouri N., Rochelle J., Dadali E.L., et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 2004, 36:449-451.
69. Carelli V., Musumeci O., Caporali L., Zanna C., La Morgia C., Del Dotto V., et al. Syndromic parkinsonism and dementia associated with OPA1 missense mutations. Ann Neurol 2015 Mar 26, [Epub ahead of print]. 10.1002/ana.24410.
70. Devi L., Raghavendran V., Prabhu B.M., Avadhani N.G., Anandatheerthavarada H.K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 2008, 283:9089-9100.
71. Xie W., Chung K.K. Alpha-synuclein impairs normal dynamics of mitochondria in cell and animal models of Parkinson's disease. J Neurochem 2012, 122:404-414.
72. Nakamura K., Nemani V.M., Azarbal F., Skibinski G., Levy J.M., Egami K., et al. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol Chem 2011, 286:20710-20726.
73. De Mena L., Coto E., Sanchez-Ferrero E., Ribacoba R., Guisasola L.M., Salvador C., et al. Mutational screening of the mortalin gene (HSPA9) in Parkinson's disease. J Neural Transm 2009, 116:1289-1293.
74. Jin J., Hulette C., Wang Y., Zhang T., Pan C., Wadhwa R., et al. Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol Cell Proteomics 2006, 5:1193-1204.
75. Liu F.T., Chen Y., Yang Y.J., Yang L., Yu M., Zhao J., et al. Involvement of mortalin/GRP75/mthsp70 in the mitochondrial impairments induced by A53T mutant alpha-synuclein. Brain Res 2015, 1604:52-61.
76. Clark I.E., Dodson M.W., Jiang C., Cao J.H., Huh J.R., Seol J.H., et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006, 441:1162-1166.
77. Park J., Lee S.B., Lee S., Kim Y., Song S., Kim S., et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006, 441:1157-1161.
78. Deng H., Dodson M.W., Huang H., Guo M. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc Natl Acad Sci U S A 2008, 105:14503-14508.
79. Grunewald A., Gegg M.E., Taanman J.W., King R.H., Kock N., Klein C., et al. Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology. Exp Neurol 2009, 219:266-273.
80. Ziviani E., Tao R.N., Whitworth A.J. Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin. Proc Natl Acad Sci U S A 2010, 107:5018-5023.
81. Dagda R.K., Cherra S.J., Kulich S.M., Tandon A., Park D., Chu C.T. Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. J Biol Chem 2009, 284:13843-13855.
82. Wang X., Yan M.H., Fujioka H., Liu J., Wilson-Delfosse A., Chen S.G., et al. LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet 2012, 21:1931-1944.
83. Stafa K., Tsika E., Moser R., Musso A., Glauser L., Jones A., et al. Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily. Hum Mol Genet 2014, 23:2055-2077.
84. Niu J., Yu M., Wang C., Xu Z. Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein. J Neurochem 2012, 122:650-658.
85. Wang X., Petrie T.G., Liu Y., Liu J., Fujioka H., Zhu X. Parkinson's disease-associated DJ-1 mutations impair mitochondrial dynamics and cause mitochondrial dysfunction. J Neurochem 2012, 121:830-839.
86. Santos D., Esteves A.R., Silva D.F., Januario C., Cardoso S.M. The impact of mitochondrial fusion and fission modulation in sporadic Parkinson's disease. Mol Neurobiol 2014 Sep 14, [Epub ahead of print]. 10.1007/s12035-014-8893-4.
87. Bender A., Krishnan K.J., Morris C.M., Taylor G.A., Reeve A.K., Perry R.H., et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006, 38:515-517.
88. Youle R.J., van der Bliek A.M. Mitochondrial fission, fusion, and stress. Science 2012, 337:1062-1065.
89. Swart C., Haylett W., Kinnear C., Johnson G., Bardien S., Loos B. Neurodegenerative disorders: dysregulation of a carefully maintained balance?. Exp Gerontol 2014, 58:279-291.
90. Wang M., Kaufman R.J. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat Rev Cancer 2014, 14:581-597.
91. Hoozemans J.J., van Haastert E.S., Eikelenboom P., de Vos R.A., Rozemuller J.M., Scheper W. Activation of the unfolded protein response in Parkinson's disease. Biochem Biophys Res Commun 2007, 354:707-711.
92. Mercado G., Valdes P., Hetz C. An ERcentric view of Parkinson's disease. Trends Mol Med 2013, 19:165-175.
93. Bellucci A., Navarria L., Zaltieri M., Falarti E., Bodei S., Sigala S., et al. Induction of the unfolded protein response by alpha-synuclein in experimental models of Parkinson's disease. J Neurochem 2011, 116:588-605.
94. Colla E., Coune P., Liu Y., Pletnikova O., Troncoso J.C., Iwatsubo T., et al. Endoplasmic reticulum stress is important for the manifestations of alpha-synucleinopathy in vivo. J Neurosci 2012, 32:3306-3320.
95. Smith W.W., Jiang H., Pei Z., Tanaka Y., Morita H., Sawa A., et al. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum Mol Genet 2005, 14:3801-3811.
96. Cooper A.A., Gitler A.D., Cashikar A., Haynes C.M., Hill K.J., Bhullar B., et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006, 313:324-328.
97. Bouman L., Schlierf A., Lutz A.K., Shan J., Deinlein A., Kast J., et al. Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress. Cell Death Differ 2011, 18:769-782.
98. Li L., Hu G.K. Pink1 protects cortical neurons from thapsigargin-induced oxidative stress and neuronal apoptosis. Biosci Rep 2015, 35:e00174.
99. Yokota T., Sugawara K., Ito K., Takahashi R., Ariga H., Mizusawa H. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem Biophys Res Commun 2003, 312:1342-1348.
100. Vitte J., Traver S., Maues De Paula A., Lesage S., Rovelli G., Corti O., et al. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease. J Neuropathol Exp Neurol 2010, 69:959-972.
101. Tan Y.Y., Zhou H.Y., Wang Z.Q., Chen S.D. Endoplasmic reticulum stress contributes to the cell death induced by UCH-L1 inhibitor. Mol Cell Biochem 2008, 318:109-115.
102. Jara J.H., Genc B., Cox G.A., Bohn M.C., Roos R.P., Macklis J.D., et al. Corticospinal motor neurons are susceptible to increased ER stress and display profound degeneration in the absence of UCHL1 function. Cereb Cortex 2015 Jan 16, [Epub ahead of print]. 10.1093/cercor/bhu318.
103. Suzuki T., Shimoda M., Ito K., Hanai S., Aizawa H., Kato T., et al. Expression of human Gaucher disease gene GBA generates neurodevelopmental defects and ER stress in Drosophila eye. PLoS One 2013, 8:e69147.
104. Maor G., Rencus-Lazar S., Filocamo M., Steller H., Segal D., Horowitz M. Unfolded protein response in Gaucher disease: from human to Drosophila. Orphanet J Rare Dis 2013, 8:140.
105. 2+ close to IP3-sensitive channels that are sensed by neighboring mitochondria. Science 1993, 262:744-747.
106. Naon D., Scorrano L. At the right distance: ER-mitochondria juxtaposition in cell life and death. Biochim Biophys Acta 1843, 2014:2184-2194.
107. Cali T., Ottolini D., Brini M. Calcium and endoplasmic reticulum-mitochondria tethering in neurodegeneration. DNA Cell Biol 2013, 32:140-146.
108. Cali T., Ottolini D., Negro A., Brini M. Enhanced parkin levels favor ER-mitochondria crosstalk and guarantee Ca(2+) transfer to sustain cell bioenergetics. Biochim Biophys Acta 1832, 2013:495-508.
109. Ottolini D., Cali T., Negro A., Brini M. The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering. Hum Mol Genet 2013, 22:2152-2168.
110. Guardia-Laguarta C., Area-Gomez E., Rub C., Liu Y., Magrane J., Becker D., et al. Alpha-synuclein is localized to mitochondria-associated ER membranes. J Neurosci 2014, 34:249-259.
111. Cali T., Ottolini D., Negro A., Brini M. Alpha-synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. J Biol Chem 2012, 287:17914-17929.
112. Gandhi S., Wood-Kaczmar A., Yao Z., Plun-Favreau H., Deas E., Klupsch K., et al. PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol Cell 2009, 33:627-638.
113. Akundi R.S., Huang Z., Eason J., Pandya J.D., Zhi L., Cass W.A., et al. Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice. PLoS One 2011, 6:e16038.
114. Marongiu R., Spencer B., Crews L., Adame A., Patrick C., Trejo M., et al. Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson's disease by disturbing calcium flux. J Neurochem 2009, 108:1561-1574.
115. Poston C.N., Krishnan S.C., Bazemore-Walker C.R. In-depth proteomic analysis of mammalian mitochondria-associated membranes (MAM). J Proteomics 2013, 79:219-230.
116. Area-Gomez E., Del Carmen Lara Castillo M., Tambini M.D., Guardia-Laguarta C., de Groof A.J., Madra M., et al. Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. EMBO J 2012, 31:4106-4123.
117. Stoica R., De Vos K.J., Paillusson S., Mueller S., Sancho R.M., Lau K.F., et al. ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43. Nat Commun 2014, 5:3996.
118. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
119. Dzamko N., Geczy C.L., Halliday G.M. Inflammation is genetically implicated in Parkinson's disease. Neuroscience 2014 Oct 22, [Epub ahead of print]. 10.1016/j.neuroscience.2014.10.028.
120. Stojkovska I., Wagner B.M., Morrison B.E. Parkinson's disease and enhanced inflammatory response. Exp Biol Med 2015 Mar 13, [Epub ahead of print]. 10.1177/1535370215576313.
121. Codolo G., Plotegher N., Pozzobon T., Brucale M., Tessari I., Bubacco L., et al. Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies. PLoS One 2013, 8:e55375.
122. Watson M.B., Richter F., Lee S.K., Gabby L., Wu J., Masliah E., et al. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp Neurol 2012, 237:318-334.
123. Gao H.M., Kotzbauer P.T., Uryu K., Leight S., Trojanowski J.Q., Lee V.M. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 2008, 28:7687-7698.
124. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290:985-989.
125. Moehle M.S., Webber P.J., Tse T., Sukar N., Standaert D.G., DeSilva T.M., et al. LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci 2012, 32:1602-1611.
126. Gillardon F., Schmid R., Draheim H. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience 2012, 208:41-48.
127. Tran T.A., Nguyen A.D., Chang J., Goldberg M.S., Lee J.K., Tansey M.G. Lipopolysaccharide and tumor necrosis factor regulate Parkin expression via nuclear factor-kappa B. PLoS One 2011, 6:e23660.
128. Chung J.Y., Park H.R., Lee S.J., Lee S.H., Kim J.S., Jung Y.S., et al. Elevated TRAF2/6 expression in Parkinson's disease is caused by the loss of Parkin E3 ligase activity. Lab Invest 2013, 93:663-676.
129. Trudler D., Weinreb O., Mandel S.A., Youdim M.B., Frenkel D. DJ-1 deficiency triggers microglia sensitivity to dopamine toward a pro-inflammatory phenotype that is attenuated by rasagiline. J Neurochem 2014, 129:434-447.